



COPY OF PAPERS
ORIGINALLY FILED

1646 \$
#10/B
2/10/02
TECH CENTER 1600/2900
RECEIVED
FEB 07 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Shaughnessy et al.

Serial No: 09/491,982

Filed: January 27, 2000

For: OSTEOPOROSIS TREATMENT

Attorney Docket No. MDSP-P02-180

Art Unit: 1646

Examiner: Prasad, S.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

January 16, 2002

Date of Signature
and of Mail Deposit


Dawn Harmon

Assistant Commissioner of Patents
Washington, D.C. 20231

REPLY UNDER 37 CFR 1.111

Sir:

In response to the Office Action mailed July 16, 2001, in connection with the above application, Applicants submit this reply. The time period for response has been extended to January 16, 2002, by the accompanying petition for a three-month extension of time. Please enter the following amendments:

In the specification:

On page 10, please replace the entirety of the last full paragraph with:

B, Additionally, SEQ ID NO. 6 depicts the amino acid sequence of an IL-11 binding region identified within the human IL-11R, namely: Ser Ile Leu Arg Pro Asp Pro Pro Gln Gly Leu Arg Val Glu Ser Val Pro Gly Tyr Pro. The corresponding murine sequence is depicted in SEQ ID NO. 8 and is: Ser Ile Leu Arg Pro Asp Pro Pro Gln Gly Leu Arg Val Glu Ser Val Pro Ser Tyr Pro. These sequences differ in their eighteenth amino acid whereby the human peptide has Gly and the murine sequence has Ser. Gly and Ser are both relatively small amino acid residues, having